...
首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S.
【24h】

Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S.

机译:在没有流感嗜血杆菌HMC-S外排机制的情况下,L22核糖体蛋白改变无法增加大环内酯类MIC。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Haemophilus influenzae HMC-C with high-level macrolide resistance after multi-step selection by clarithromycin reverted spontaneously and became hypersusceptible to macrolides. OBJECTIVE: Determination of macrolide resistance mechanism(s) in hypersusceptible and hyperresistant strains. METHODS: The presence of macrolide efflux in the strains was studied by radioactive erythromycin accumulation. Ribosomal mutations were investigated by sequencing. The possible role of acrAB clusters in macrolide resistance was studied by sequencing and expression analysis. RESULTS: The parent strain had no ribosomal alteration, but both high-level resistant and hypersusceptible strains had R88P mutations in ribosomal protein L22. Radioactive macrolide accumulation studies pointed to the presence of macrolide efflux in the high-level resistant and parent strains, but not in the hypersusceptible derivative. Transformation of hypersusceptible strains using total DNA from the parent strain restored the macrolideefflux system in the hypersusceptible strain, which was confirmed by MIC levels and radioactive erythromycin accumulation similar to that of the mutant resistant strain. Analysis of sequence and transcription of acrAB gene clusters showed no significant differences between resistant and hypersusceptible derivatives. CONCLUSION: Mutation in ribosomal protein L22 alone does not confer high-level macrolide resistance unless efflux is present.
机译:背景:克拉霉素经多步选择后,具有高水平大环内酯类耐药性的流感嗜血杆菌HMC-C自发恢复,对大环内酯类药物易感。目的:确定高敏感性和高耐药性菌株的大环内酯类耐药机制。方法:通过放射性红霉素积聚研究菌株中大环内酯的外排。通过测序研究核糖体突变。通过测序和表达分析研究了acrAB簇在大环内酯抗性中的可能作用。结果:亲本菌株没有核糖体变异,但高抗性和高敏感性菌株在核糖体蛋白L22中均具有R88P突变。放射性大环内酯蓄积研究指出,在高水平抗药性和亲本菌株中存在大环内酯流出,而在高敏感性衍生物中则没有。使用来自亲本菌株的总DNA转化高敏感性菌株,恢复了高敏感性菌株中的大环内酯外流系统,这通过MIC水平和与突变抗性菌株相似的放射性红霉素积累来证实。 acrAB基因簇的序列和转录分析表明,抗药性和高药敏性衍生物之间无显着差异。结论:仅存在核糖体蛋白L22突变不会赋予高水平大环内酯类药物耐药性,除非存在外排。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号